Login to Your Account

Turnstone takes flight with $11M series A round

By Cormac Sheridan
Staff Writer

Wednesday, October 28, 2015
DUBLIN – Turnstone Biologics Inc. raised $11.3 million in a series A round to take forward a novel oncolytic virus platform, based on a modified rhabdovirus strain that has strong immune-boosting properties as well as systemic oncolytic activity.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription